Durgical
EN
Open the app

T-cell receptor signalling and the immune synapse (where drugs act)

  • Process

When a T cell recognises its antigen, a chain of enzymes carries the message to the nucleus to make IL-2; transplant drugs cut this chain at specific links.

Updated

What it is

Antigen recognition by the T-cell receptor is converted into gene activation by a cascade of kinases, adaptors and second messengers. The contact zone between T cell and antigen-presenting cell becomes an organised immune synapse. The pathway ends in three transcription factors, NFAT, NF-κB and AP-1, that switch on IL-2 and other genes. Calcineurin inhibitors, mTOR inhibitors and costimulation blockers act at defined steps, and inherited defects in the pathway cause combined immunodeficiency.

Key facts

  • Immune synapse: TCR and CD28 cluster in the centre (cSMAC), LFA-1–ICAM-1 adhesion forms a ring around them (pSMAC).
  • Cyclosporine and tacrolimus bind different proteins (cyclophilin, FKBP12) but both inhibit calcineurin.
  • Sirolimus binds FKBP12 like tacrolimus, but the complex inhibits mTOR instead of calcineurin.
  • Tacrolimus is a calcineurin inhibitor that is a frequent cause of post-transplant diabetes; cyclosporine causes gingival overgrowth and hirsutism.

Step by step

  1. TCR binds peptide–MHC; CD4 or CD8 binds the same MHC and brings the kinase Lck.
  2. Lck phosphorylates ITAMs on CD3 and ζ chains; the kinase ZAP-70 docks there and is activated.
  3. ZAP-70 phosphorylates the adaptors LAT and SLP-76, which recruit PLCγ1 and Ras activators.
  4. PLCγ1 makes IP3 (calcium release → calcineurin → NFAT enters the nucleus) and DAG (PKCθ → NF-κB).
  5. Ras–MAP kinase signalling produces AP-1; NFAT, NF-κB and AP-1 together switch on IL-2.
  6. CD28 binding B7 adds PI3K–Akt–mTOR signals for survival, metabolism and proliferation.
  7. IL-2 binds its receptor and, through JAK–STAT and mTOR, drives clonal expansion.

Drugs and defects along the pathway

StepDrug or defectEffect
B7–CD28 costimulationAbatacept, belatacept (CTLA-4–Ig)Block signal 2; used in RA and kidney transplant
Calcineurin → NFATCyclosporine (with cyclophilin), tacrolimus (with FKBP12)No NFAT, little IL-2; nephrotoxicity, hypertension, neurotoxicity
mTORSirolimus, everolimus (with FKBP12)Block response to IL-2 and proliferation; impaired wound healing, hyperlipidaemia
IL-2 receptor α (CD25)BasiliximabInduction therapy in transplantation
ZAP-70Inherited ZAP-70 deficiencyAbsent CD8 cells, non-functional CD4 cells: combined immunodeficiency
Lck, CD3 chainsRare inherited defectsCombined immunodeficiency

Common traps

  • Tacrolimus and sirolimus act alike because both bind FKBP12: the tacrolimus complex blocks calcineurin, while the sirolimus complex blocks mTOR.
  • Cyclosporine blocks the IL-2 receptor signal: it blocks IL-2 transcription through calcineurin–NFAT; blocking the response to IL-2 is what mTOR inhibitors do.
  • ZAP-70 deficiency means no T cells: CD4 cells are present but non-functional and CD8 cells are absent, so total lymphocytes can look normal.
  • Abatacept is an anti-CD28 antibody: it is CTLA-4–Ig, a fusion protein that grabs B7 (CD80/CD86) so CD28 receives no signal 2.

Test yourself

Think of the answer, then tap the question to see it.

Which phosphatase do cyclosporine and tacrolimus inhibit, and which transcription factor stays out of the nucleus?

Calcineurin; NFAT stays phosphorylated in the cytoplasm, so IL-2 is not transcribed.

Why can sirolimus be combined with a calcineurin inhibitor without simply duplicating it?

They hit different steps: calcineurin inhibitors stop IL-2 being transcribed, while sirolimus blocks mTOR signals downstream of the IL-2 receptor and other growth signals.

An infant with severe infections has normal CD4 counts but no CD8 T cells, and the CD4 cells do not proliferate to antigen. Which kinase is defective?

ZAP-70, recruited to phosphorylated CD3/ζ ITAMs; without it TCR signals fail, and CD8 cells are lost during thymic selection.

Add to my cards (3)

Connections

← All of immunology

Educational content on the immune system; not a treatment or individual vaccination guide and no substitute for a health professional's advice. No doses are given.

Sources: Tacrolimus (MedlinePlus, US National Library of Medicine, 2024); Transplant rejection (MedlinePlus, US National Library of Medicine, 2024).

Spotted a mistake?We are always improving for the community. Tell us what is wrong and our team will review it.Report a mistake

Representative model, for educational purposes only.